drugset / Trial / NCT06680375
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
RandomizedParallel-groupTriple-blindPrevention
Summary
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.
Timeline
- Start
- 2024-11-11
- Primary completion
- 2025-06-09
- Completion
- 2025-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COVID-19 mRNA | Messenger RNA (mRNA) | — | — |
| Subject | Flu Seasonal | Vaccine | — | — |
| Subject | Flu Seasonal /SARS-CoV-2 mRNA | Messenger RNA (mRNA) | — | — |
| Subject | Flu Seasonal mRNA | Messenger RNA (mRNA) | — | — |
| Subject | SARS-CoV-2 mRNA | Messenger RNA (mRNA) | — | — |